Literature DB >> 6262952

Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.

J Chodos, E L Francke, M Saltzman, H C Neu.   

Abstract

The pharmacokinetics of intravenously administered cefotaxime were studied in 11 patients with creatinine clearances of less than 7 ml/min who were undergoing chronic hemodialysis. Eight were studied during dialysis, and 3 were studied between dialyses. Pharmacokinetic parameters were determined using a two-compartment linear model. The serum half-life of cefotaxime off dialysis ranged from 1.48 to 3.78 hr. The half-life during dialysis was 2.52 +/- 0.34 hr. There was a 28% reduction in serum concentration per hour. A dosage schedule for the use of intravenously administered cefotaxime in patients undergoing hemodialysis is presented.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6262952

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

Authors:  S Srinivasan; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Tolerance in patients with terminal renal insufficiency of high doses of cefotaxime.

Authors:  D Höffler; T Wittgens; C Piper
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 4.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.